Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Update

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the recipient of a significant drop in short interest in the month of August. As of August 15th, there was short interest totalling 1,780,000 shares, a drop of 5.8% from the July 31st total of 1,890,000 shares. Approximately 2.1% of the shares of the company are short sold. Based on an average trading volume of 396,400 shares, the short-interest ratio is currently 4.5 days.

Analysts Set New Price Targets

CMPX has been the topic of a number of analyst reports. Wedbush reiterated an “outperform” rating and set a $8.00 price objective on shares of Compass Therapeutics in a research note on Wednesday, August 7th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Compass Therapeutics in a report on Monday, August 12th.

Hedge Funds Weigh In On Compass Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Simplicity Wealth LLC bought a new position in Compass Therapeutics in the 1st quarter worth about $80,000. Bleakley Financial Group LLC bought a new position in shares of Compass Therapeutics in the first quarter worth approximately $80,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Compass Therapeutics during the second quarter valued at approximately $41,000. Panagora Asset Management Inc. bought a new stake in shares of Compass Therapeutics during the second quarter valued at approximately $68,000. Finally, Ground Swell Capital LLC bought a new stake in shares of Compass Therapeutics during the second quarter valued at approximately $124,000. 68.43% of the stock is currently owned by institutional investors.

Compass Therapeutics Price Performance

CMPX opened at $1.51 on Wednesday. The firm has a market capitalization of $207.76 million, a P/E ratio of -4.19 and a beta of 0.79. Compass Therapeutics has a one year low of $0.77 and a one year high of $2.43. The company has a fifty day moving average price of $1.08 and a 200-day moving average price of $1.44.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.10) EPS for the quarter, hitting analysts’ consensus estimates of ($0.10). The company had revenue of $0.85 million during the quarter. On average, analysts expect that Compass Therapeutics will post -0.42 earnings per share for the current year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.